Important factors in compliance with HIV regimens identified; and more

November 20, 2006

Adherence to HIV medications is the greatest predictor of death. How well patients with HIV adhere to their regimens of highly active antiretroviral therapy (HAART) medication depends on a variety of factors, either positive or negative, many of which are common to patients around the world. In a systematic review of previously published studies researchers, Edward Mills and colleagues, looked at studies in both developed and developing country settings which had examined the factors that affect adherence to these regimens.

84 relevant studies were examined of which 37 used "qualitative" methods (focus groups, interviews, open-ended questioning) and 47 used "quantitative" methods (surveys). Only 12 of the studies had been carried out in the developing world.

Many barriers to adherence were common to both developed and developing settings, including fear of disclosure of HIV status, concomitant substance abuse, forgetfulness, suspicions of treatment, regimens that were too complicated, number of pills required, decreased quality of life, and work and family responsibilities. Factors unique to the studies conducted in the developing world included financial constraints and problems with traveling to get access to treatment.

Important facilitators (factors that made adherence easier) reported by patients in developed nation settings included having a sense of self-worth, seeing positive effects of antiretroviral drugs, acceptance of HIV status, understanding of the need for strict adherence, making use of reminder tools, and having a simple regimen. No facilitators to adherence were discussed in any study in a developing nation setting.

The authors conclude that "clinicians should use this information to engage in open discussion with patients to promote adherence and identify barriers and facilitators within their own populations". However, they note that in developing country settings, "the reliability of medication access is an important adherence barrier that individuals have little opportunity to facilitate. Patient-level adherence can be determined only when a steady supply of medication exists."

Citation: Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to antiretroviral therapy: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3(11): e438.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030438

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-11-mills.pdf

An eLetter will be also published on the 21st November in response to the article. You will be able to view this via the Read Other Responses link.

CONTACT:

Curtis Cooper, MD, FRCPC
Associate Professor of Medicine
University of Ottawa
Division of Infectious Diseases
The Ottawa Hospital, Canada
+1-613-737-8924 (office)
+1-613-737-8164 (fax)
ccooper@Ottawahospital.on.ca




Complement Lysis of HIV In Vivo

The role that humoral immunity plays in fighting HIV infection is complex and poorly understood. In particular, it is not clear whether the complement system helps to stop the spread of HIV or whether it inadvertently helps it to spread by facilitating its entry into macrophages, one of the cell types in which it replicates. Results from Alexandra Trkola and colleagues that antibody-mediated complement lysis of HIV in the laboratory is inversely related to a patient's viral load during acute infection suggest that the complement system contributes to the control of HIV at the early stages. But, because complement levels vary during HIV infections, future work is needed to determine the importance of this form of humoral immunity in combating HIV, particularly since complement has the potential to enhance as well as block viral spread. Nevertheless, the results of this study suggest that complement activating antibodies should be considered in future attempts to design an effective HIV vaccine.

Citation: Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, et al. (2006) Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 3(11): e441.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030441

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-11-trkola.pdf

CONTACT:

Alexandra Trkola
University Hospital Zurich
Division of Infectious Diseases
Ramistrasse 100
Zurich, ZH 8091 Switzerland
+41-44-255-5976
+41-44-2553291 (fax)
alexandra.trkola@usz.ch
-end-
* * * * * * * * EMBARGO: MONDAY, 20 November, 5 P.M. PST * * * * * * *

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

PLOS

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.